Bioxytran Inc
OTC:BIXT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
New Zealand King Salmon Co Ltd
ASX:NZK
|
NZ |
|
European Green Transition PLC
LSE:EGT
|
UK |
|
Sanvo Fine Chemicals Group Ltd
HKEX:301
|
CN |
|
Delphi World Money Ltd
BSE:533452
|
IN |
|
M
|
Mitra Angkasa Sejahtera PT Tbk
IDX:BAUT
|
ID |
|
ICO Group Ltd
HKEX:1460
|
HK |
|
A
|
Accel Solutions Group Ltd
TASE:ACCL
|
IL |
|
S
|
Sharat Industries Ltd
BSE:519397
|
IN |
|
G
|
Gasporox AB (publ)
STO:GPX
|
SE |
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Bioxytran Inc
OTC:BIXT
|
3.7m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
375.5B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
191.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
176.3B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.5B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.2B USD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
67.6B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
Bioxytran Inc
Glance View
BioXyTran, Inc. engages in the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen in tissues. The company is headquartered in Needham, Massachusetts. The company went IPO on 2010-01-05. The Company’s lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application that includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiaries, provides lead pharmaceutical drug candidate, ProLectin-Rx. ProLectin-Rx is a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, which is a type of galectin.
